glp-1 gastroparesis class action in west virginia Lawsuit Nutritional priorities to support GLP-1

Their rapid adoption underscores just how quickly the treatment paradigm has shifted

Risk of bias: all four RCTs were rated low risk by RoB2 (with some concerns for open-label outcome ascertainment in three trials, a domain-specific issue that does not alter the overall RoB2 category from low)

Adverse events were predominantly mild gastrointestinal symptoms

Few categories in modern medicine have captured the imagination of patients, physicians, and investors as quickly as GLP-1 receptor agonists (GLP-1s)

These figures highlight how, even with broader coverage, patient behavior and systemic barriers continue to erode both demand and health outcomes in this rapidly evolving market